Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00004054
Completed
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +53 locations
Conditions: Prostate Cancer
Register for Updates
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
NCT01745367
Terminated
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/05/2020
Locations: Not set, Birmingham, Alabama +53 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Hematology and Oncology Associates of Alabama, Birmingham, Alabama +34 locations
Conditions: Lung Cancer
Register for Updates
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
NCT02631876
Completed
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/24/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +130 locations
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Register for Updates
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222
Completed
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Gender:
FEMALE
Ages:
60 years and below
Trial Updated:
09/11/2020
Locations: Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas +77 locations
Conditions: Breast Cancer
Register for Updates
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT02289898
Completed
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/07/2020
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +41 locations
Conditions: Pancreatic Cancer
Register for Updates
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
NCT01572038
Completed
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2020
Locations: CPMC; Service d'Oncologie Médicale, Algiers, Not set +298 locations
Conditions: Breast Neoplasms
Register for Updates
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
NCT01369433
Terminated
Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the invest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2020
Locations: Translational Genomics Research Institute (TGEN), Scottsdale, Arizona +48 locations
Conditions: Solid Tumors
Register for Updates
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970
Completed
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2020
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +156 locations
Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Register for Updates
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
NCT01218516
Completed
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2020
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +92 locations
Conditions: Adenocarcinoma of the Lung
Register for Updates
EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
NCT02001272
Completed
The current standard of first-line chemotherapy in advanced ovarian cancer is the combination of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-². This combination is feasible in selected elderly patients such as those included in prospective trials. These trials, however, include a minority of the elderly population. In wider selection of patients \>70 years old, the standard carboplatin-paclitaxel regimen has been shown to induce an excess of toxicity and premature treatment stopping. For... Read More
Gender:
FEMALE
Ages:
70 years and above
Trial Updated:
08/03/2020
Locations: Notre-Dame Hospital of the CHUM, Montréal, Not set +62 locations
Conditions: Ovarian Cancer
Register for Updates
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
NCT02715804
Terminated
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2020
Locations: University of South Alabama, Mobile, Alabama +216 locations
Conditions: Pancreatic Ductal Carcinoma
Register for Updates